Rheumatoid Arthritis
Conditions
Keywords
moderate Rheumatoid Arthritis, severe Rheumatoid Arthritis, subcutaneous, Olokizumab
Brief summary
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving but not fully responding to treatment with methotrexate (MTX). The primary objective of this study was to evaluate the efficacy of OKZ 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active RA inadequately controlled by MTX therapy. The secondary objective was to evaluate the efficacy of OKZ relative to adalimumab in subjects with moderately to severely active RA inadequately controlled by MTX therapy.
Detailed description
The goal of this Phase III study was to assess the efficacy, safety and tolerability of OKZ in subjects with moderately to severely active RA who had responded inadequately to MTX. The primary endpoint of the trial was at Week 12. Olokizumab was expected to reduce the disease activity and improve physical function. The study was expected to provide safety information in a large group of subjects over at least a 24 week period. This study included a 4-week Screening Period, a double-blind Treatment Period from Week 0 to Week 24, and a Safety Follow-Up Period from Week 24 to Week 44. Subjects were assessed for eligibility to enter the study during the 4-week Screening Period. A total of 1575 subjects were planned to be randomly assigned to 1 of 4 treatment groups in a 2:2:2:1 ratio (450, 450, 450, and 225 subjects per group, respectively): 1. Olokizumab 64 mg q4w: SC injection of OKZ 64 mg q4w (alternating with SC injection of placebo q4w to maintain blinding) + MTX 2. Olokizumab 64 mg q2w: SC injection of OKZ 64 mg q2w + MTX 3. Adalimumab 40 mg q2w: SC injection of adalimumab 40 mg q2w + MTX 4. Placebo: SC injection of placebo q2w + MTX Throughout the double-blind Treatment Period, all subjects were required to remain on a stable dose of background MTX with a stable route of administration. Concomitant treatment with folic acid was required for all subjects. The last dose of study treatment (OKZ, adalimumab, or placebo) was at Week 22 in all groups. Following Visit 2 (randomization; Week 0), subjects returned to the study site at least every 2 weeks through Week 24 for response and safety assessments. At Week 14, subjects who had not improved by at least 20% in both swollen and tender joint counts were classified as nonresponders and were administered sulfasalazine and/or hydroxychloroquine as rescue medication in addition to the assigned treatment. After completion of the 24-week double-blind Treatment Period, subjects either rolled over into the long-term open-label extension (OLE) study or entered the Safety Follow-Up Period. During the Safety Follow-Up Period, subjects returned for visits +4, +8, and +22 weeks after the last dose of study treatment. Subjects who had discontinued randomized treatment prematurely were required to come for the End of Treatment (EoT) Visit 2 weeks after the last study treatment administration and then continue with the scheduled study visits. Adverse events (AEs) were assessed throughout the study (starting when the subject signed the informed consent form) and evaluated using the Common Terminology Criteria for Adverse Events Version 4.0. There was ongoing monitoring of safety events, including laboratory findings, by the Sponsor or the Sponsor's designee. In addition, safety was assessed throughout the study by an independent Data Safety Monitoring Board and potential major adverse cardiac events were evaluated by an independent Cardiovascular Adjudication Committee. The study was conducted at 208 sites across 18 countries globally (in US, European Union (EU),United Kingdom (UK), Russian Federation, Asia, Latin America).
Interventions
DRUGOlokizumab 64mg q4w
160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
DRUGOlokizumab 64mg q2w
160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
DRUGAdalimumab 40mg q2w
0.4 or 0.8 mL prefilled, single-dose syringe
DRUGPlacebo q2w
sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
Sponsors
Quintiles, Inc.
OCT Clinical Trials
R-Pharm International, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects willing and able to sign informed consent * Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised classification criteria for RA for at least 12 weeks prior to Screening. (If the subject was diagnosed according to ACR 1987 criteria previously, the Investigator may classify the subject per ACR 2010 retrospectively, using available source data) * Inadequate response to treatment with oral, SC, or intramuscular MTX (defined as a subject with at least 12 weeks of exposure prior to Screening and with either absence of any documented clinically significant response, or documented initial clinical response with subsequent loss of that response or partial response) for at least 12 weeks prior to Screening at a dose of 15 to 25 mg/week (or ≥10 mg/week if intolerant to higher doses). The dose and route of administering MTX had to have been stable for at least 6 weeks prior to Screening. A lower dose of MTX (≥7.5 mg/week) was permitted for subjects enrolled in the Republic of Korea, consistent with local clinical practice. * Subjects must be willing to take folic acid or equivalent throughout the study. * Subjects must have moderately to severely active RA disease as defined by all of the following: * ≥6 tender joints (68 joint count) at Screening and baseline; and * ≥6 swollen joints (66 joint count) at Screening and baseline; and * CRP above the normal range (ULN) at Screening based on the central laboratory results.
Exclusion criteria
* Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (eg, gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile idiopathic arthritis, or systemic lupus erythematosus). However, subjects could have secondary Sjogren's syndrome or hypothyroidism. * Subjects who are Steinbrocker class IV functional capacity (incapacitated, largely or wholly bed-ridden or confined to a wheelchair, with little or no self-care) * Prior exposure to any licensed or investigational compound directly or indirectly targeting IL 6 or IL 6R (including tofacitinib or other Janus kinases and spleen tyrosine kinase \[SYK\] inhibitors) * Prior treatment with cell depleting therapies including anti CD20 or investigational agents (e.g., CAMPATH, anti CD4, anti CD5, anti CD3, and anti CD19) * Prior use of bDMARDs * Use of parenteral and/or intra-articular glucocorticoids within 4 weeks prior to baseline * Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent) or change in dosage within 2 weeks prior to baseline * Prior documented history of no response to hydroxychloroquine and sulfasalazine * Prior use of cDMARDs (other than MTX) within the following windows prior to baseline (cDMARDs should not be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA): 1. 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine, chloroquine, gold, penicillamine, minocycline, or doxycycline 2. 12 weeks for leflunomide unless the subject has completed the following elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a dosage of 50 grams 4 times daily for at least 24 hours 3. 24 weeks for cyclophosphamide * Vaccination with live vaccines in the 6 weeks prior to baseline or planned vaccination with live vaccines during the study * Participation in any other investigational drug study within 30 days or 5 times the terminal half-life of the investigational drug, whichever is longer, prior to baseline * Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to baseline * Use of intra-articular hyaluronic acid injections within 4 weeks prior to baseline * Use of non-steroidal anti-inflammatory drugs (NSAIDs) on unstable dose or switching of NSAIDs within 2 weeks prior to baseline * Previous participation in this study (randomized) or another study of OKZ * Subjects with concurrent acute or chronic viral hepatitis B or C infection as detected by blood tests at Screening(e.g., positive for hepatitis B surface antigen \[HBsAg\], total hepatitis B core antibody \[anti-HBc\], or hepatitis C virus antibody \[HCV Ab\]). Subjects who are are positive for hepatitis B surface antibodies (anti-HBs), but negative for HBsAg and anti-HBc, will be eligible * Subjects with human immunodeficiency virus (HIV) infection * Subjects with: 1. Suspected or confirmed current active TB disease or a history of active TB disease 2. Close contact (i.e., sharing the same household or other enclosed environment, such as a social gathering place, workplace, or facility, for extended periods during the day) with an individual with active TB within 1.5 years prior to Screening * Concurrent malignancy or a history of malignancy within the last 5 years (with the exception of successfully treated carcinoma of the cervix in situ and successfully treated basal cell carcinoma and squamous cell carcinoma not less than 1 year prior to Screening \[and no more than 3 excised skin cancers within the last 5 years prior to Screening\]) * Subjects with any infection requiring oral antibiotic or antiviral therapy in the 2 weeks prior to Screening or at baseline, injectable anti-infective therapy in the last 4 weeks prior to baseline, or serious or recurrent infection with history of hospitalization in the 6 months prior to baseline * Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis, meningitis, or other non-self-limited herpes zoster infections in the 6 months prior to baseline * Subjects with planned surgery during the study or surgery ≤ 4 weeks prior to Screening and from which the subject has not fully recovered, as judged by the Investigator * Subjects with diverticulitis or other symptomatic GI conditions that might predispose the subject to perforations, including subjects with history of such predisposing conditions (e.g., diverticulitis, GI perforation, or ulcerative colitis) * Pre-existing central nervous system demyelinating disorders (e.g., multiple sclerosis and optic neuritis) * History of chronic alcohol or drug abuse as judged by the Investigator * Female subjects who are pregnant, currently lactating, have lactated within the last 12 weeks, or who are planning to become pregnant during the study or within 6 months of last dose of study treatment * Female subjects of childbearing potential (unless permanent cessation of menstrual periods, determined retrospectively after a woman has experienced 12 months of natural amenorrhea as defined by the amenorrhea with underlying status (e.g., correlative age) or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone levels \>40 mIU/mL and estradiol \<20 pg/mL) who are not willing to use a highly effective method of contraception during the study and for at least 6 months after the last administration of study treatment OR Male subjects with partners of childbearing potential not willing to use a highly effective method of contraception during the study and for at least 3 months after the last administration of study treatment. * Subjects with a known hypersensitivity to any component of the OKZ drug product, adalimumab, or placebo * Subjects with a known hypersensitivity or contraindication to any component of the rescue medication * History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response | at Week 12 | The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. (where a responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12) This endpoint served to demonstrate that the efficacy of OKZ was superior to placebo. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Subjects Achieving Low Disease Activity | at Week 12 | Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) \<3.2, and remaining on randomized treatment and in the study at Week 12 |
| Percentage of Subjects Achieving Low Disease Activity: Olokizumab Comparison With Adalimumab | at Week 12 | Percentage of subjects achieving low disease activity, defined as DAS28 (CRP) \<3.2, and remaining on randomized treatment and in the study at Week 12; served to demonstrate that the efficacy of OKZ was noninferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) was demonstrated concurrently based on the same endpoint |
| Percentage of Subjects Achieving ACR20 Response: Olokizumab Comparison With Adalimumab | at Week 12 | A responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12.This endpoint served to demonstrate that the efficacy of OKZ was non-inferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) was demonstrated concurrently based on the same endpoint. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP) |
| Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response | at Week 24 | Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 24 American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP) |
| Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission) | at Week 24 | Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 24 |
| Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline to Week 12 | Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions.The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question. A decrease from baseline indicates improvement for HAQ-DI.The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome). |
Countries
Argentina, Brazil, Bulgaria, Colombia, Czechia, Estonia, Germany, Hungary, Latvia, Lithuania, Mexico, Poland, Romania, Russia, South Korea, Taiwan, United Kingdom, United States
Participant flow
Recruitment details
Enrollment was conducted at 208 clinical sites across 18 countries (US,EU,UK, Russian Federation, Asia, Latin America). 3359 subjects were screened and 1648 subjects were enrolled (randomized). A total of 1645 subjects were treated, and 1483 subjects completed the study. A total of 1648 subjects were analyzed for efficacy in the ITT Population and 1645 subjects were analyzed for safety in the Safety Population.
Participants by arm
| Arm | Count |
|---|---|
| Arm 1: Olokizumab q4w + Methotrexate Olokizumab 64mg subcutaneous q4w+ placebo+Methotrexate
64 mg Olokizumab administered subcutaneously once every 4 weeks + placebo in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) | 479 |
| Arm 2: Olokizumab q2w + Methotrexate Olokizumab 64mg subcutaneous q2w + Methotrexate
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) | 464 |
| Arm 3: Adalimumab q2w + Methotrexate Active Comparator, Adalimumab 40mg q2w subcutaneous + Methotrexate
Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) | 462 |
| Arm 4: Placebo q2w + Methotrexate Placebo subcutaneous q2w + Methotrexate
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) | 243 |
| Total | 1,648 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Death | 2 | 3 | 1 | 1 |
| Overall Study | Inadequately Enrolled | 0 | 0 | 0 | 1 |
| Overall Study | Inadequately enrolled patient refused to Follow-Up | 1 | 0 | 0 | 0 |
| Overall Study | Investigator recorded as Adverse Event | 1 | 0 | 2 | 0 |
| Overall Study | Investigator recorded as Sponsor's decision - decreased lymphocyte level | 1 | 0 | 0 | 0 |
| Overall Study | Investigator's Decision (Adverse Event) | 0 | 1 | 0 | 0 |
| Overall Study | Lack Of Efficacy Per PI | 0 | 0 | 0 | 1 |
| Overall Study | Lost to Follow-up | 1 | 7 | 4 | 6 |
| Overall Study | Patient had an upper respiratory infection and took medication that was not allowed | 1 | 0 | 0 | 0 |
| Overall Study | Personal reasons | 0 | 0 | 0 | 1 |
| Overall Study | Positive Quantiferon Testing, Patient Was Not Taken Prophylactic Medication | 1 | 0 | 0 | 0 |
| Overall Study | Study Treatment Was Terminated At The Site | 0 | 0 | 1 | 0 |
| Overall Study | Subject Did not attend treatment period visits due to misunderstanding of protocol | 1 | 0 | 1 | 0 |
| Overall Study | Subject didn't Completed Visits Schedule After Serious Adverse Event | 0 | 0 | 1 | 0 |
| Overall Study | Subject met permanent IP discontinuation criteria, did not agree for treatment period visits | 0 | 0 | 1 | 0 |
| Overall Study | Subject Taken Out Of Study Due To Sponsor Investigating Investigational Product. | 1 | 0 | 0 | 0 |
| Overall Study | The subject was early discontinued due to lab Adverse Event as per Investigator's decision | 1 | 0 | 0 | 0 |
| Overall Study | Use of prohibited Medication | 0 | 0 | 1 | 0 |
| Overall Study | Violation of Eligibility criteria | 0 | 0 | 1 | 1 |
| Overall Study | Withdrawal By PI's Decision | 0 | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 25 | 31 | 37 | 25 |
Baseline characteristics
| Characteristic | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Adalimumab q2w + Methotrexate | Arm 4: Placebo q2w + Methotrexate | Total | Arm 1: Olokizumab q4w + Methotrexate |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 85 Participants | 95 Participants | 51 Participants | 321 Participants | 90 Participants |
| Age, Categorical Between 18 and 65 years | 379 Participants | 367 Participants | 192 Participants | 1327 Participants | 389 Participants |
| Age, Continuous | 53.3 years STANDARD_DEVIATION 11.92 | 54.3 years STANDARD_DEVIATION 12.32 | 54.7 years STANDARD_DEVIATION 11.85 | 53.9 years STANDARD_DEVIATION 12.07 | 53.7 years STANDARD_DEVIATION 12.09 |
| Body Mass Index (BMI) | 28.656 kg/m^2 | 28.532 kg/m^2 | 28.573 kg/m^2 | 28.609 kg/m^2 | 28.654 kg/m^2 |
| Race/Ethnicity, Customized Asian | 10 Participants | 4 Participants | 5 Participants | 25 Participants | 6 Participants |
| Race/Ethnicity, Customized Black or African American | 20 Participants | 23 Participants | 11 Participants | 69 Participants | 15 Participants |
| Race/Ethnicity, Customized Other/Mixed | 52 Participants | 50 Participants | 24 Participants | 178 Participants | 52 Participants |
| Race/Ethnicity, Customized White | 382 Participants | 385 Participants | 203 Participants | 1376 Participants | 406 Participants |
| Region of Enrollment Argentina | 42 participants | 43 participants | 24 participants | 153 participants | 44 participants |
| Region of Enrollment Brazil | 33 participants | 30 participants | 16 participants | 112 participants | 33 participants |
| Region of Enrollment Bulgaria | 20 participants | 19 participants | 8 participants | 65 participants | 18 participants |
| Region of Enrollment Colombia | 17 participants | 16 participants | 8 participants | 59 participants | 18 participants |
| Region of Enrollment Czechia | 50 participants | 51 participants | 30 participants | 189 participants | 58 participants |
| Region of Enrollment Estonia | 3 participants | 5 participants | 1 participants | 13 participants | 4 participants |
| Region of Enrollment Germany | 13 participants | 10 participants | 6 participants | 40 participants | 11 participants |
| Region of Enrollment Hungary | 13 participants | 13 participants | 10 participants | 51 participants | 15 participants |
| Region of Enrollment Latvia | 3 participants | 0 participants | 0 participants | 4 participants | 1 participants |
| Region of Enrollment Lithuania | 22 participants | 22 participants | 8 participants | 74 participants | 22 participants |
| Region of Enrollment Mexico | 63 participants | 59 participants | 30 participants | 215 participants | 63 participants |
| Region of Enrollment Poland | 85 participants | 87 participants | 46 participants | 308 participants | 90 participants |
| Region of Enrollment Romania | 0 participants | 1 participants | 0 participants | 1 participants | 0 participants |
| Region of Enrollment Russia | 21 participants | 25 participants | 11 participants | 77 participants | 20 participants |
| Region of Enrollment South Korea | 4 participants | 1 participants | 4 participants | 11 participants | 2 participants |
| Region of Enrollment Taiwan | 3 participants | 2 participants | 1 participants | 8 participants | 2 participants |
| Region of Enrollment United Kingdom | 1 participants | 6 participants | 1 participants | 11 participants | 3 participants |
| Region of Enrollment United States | 71 participants | 72 participants | 39 participants | 257 participants | 75 participants |
| Sex: Female, Male Female | 352 Participants | 363 Participants | 190 Participants | 1283 Participants | 378 Participants |
| Sex: Female, Male Male | 112 Participants | 99 Participants | 53 Participants | 365 Participants | 101 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 2 / 477 | 3 / 463 | 1 / 462 | 1 / 243 |
| other Total, other adverse events | 177 / 477 | 183 / 463 | 129 / 462 | 71 / 243 |
| serious Total, serious adverse events | 20 / 477 | 22 / 463 | 26 / 462 | 12 / 243 |
Outcome results
Primary
Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response
The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. (where a responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12) This endpoint served to demonstrate that the efficacy of OKZ was superior to placebo. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
Time frame: at Week 12
Population: Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm 1: Olokizumab q4w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response | 342 Participants |
| Arm 2: Olokizumab q2w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response | 326 Participants |
| Arm 3: Adalimumab q2w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response | 309 Participants |
| Arm 4: Placebo q2w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response | 108 Participants |
Comparison: The OKZ ACR20 response rate for the 64 mg q4w treatment group at Week 12 was expected to be at least 50% resulting in an expected difference in ACR20 response rates of 25 percentage points between the respective OKZ treatment group and placebo. Sample size yield 100% disjunctive power for testing the primary hypothesisp-value: <0.000197.5% CI: [0.183, 0.352]Chi-squared
Comparison: The OKZ ACR20 response rate for the 64 mg q2w treatment group at Week 12 was expected to be at least 55%, resulting in an expected difference in ACR20 response rate of 30 percentage points between the respective OKZ treatment group and placebo. Sample size yield 100% disjunctive power for testing the primary hypothesisp-value: <0.000197.5% CI: [0.171, 0.341]Chi-squared
Secondary
Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI)
Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions.The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question. A decrease from baseline indicates improvement for HAQ-DI.The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).
Time frame: Baseline to Week 12
Population: Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population. Subjects with a missing baseline are not included. Data after treatment discontinuation are Included, Data after discontinuing study are multiply Imputed based on the return to baseline assumption.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Arm 1: Olokizumab q4w + Methotrexate | Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) | -0.60 score on a scale | Standard Error 0.028 |
| Arm 2: Olokizumab q2w + Methotrexate | Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) | -0.65 score on a scale | Standard Error 0.03 |
| Arm 3: Adalimumab q2w + Methotrexate | Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) | -0.61 score on a scale | Standard Error 0.029 |
| Arm 4: Placebo q2w + Methotrexate | Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) | -0.42 score on a scale | Standard Error 0.039 |
p-value: <0.000197.5% CI: [-0.33, -0.12]ANCOVA
95% CI: [-0.28, -0.1]
p-value: <0.000197.5% CI: [-0.29, -0.09]ANCOVA
Secondary
Percentage of Subjects Achieving ACR20 Response: Olokizumab Comparison With Adalimumab
A responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12.This endpoint served to demonstrate that the efficacy of OKZ was non-inferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) was demonstrated concurrently based on the same endpoint. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
Time frame: at Week 12
Population: Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm 1: Olokizumab q4w + Methotrexate | Percentage of Subjects Achieving ACR20 Response: Olokizumab Comparison With Adalimumab | 342 Participants |
| Arm 2: Olokizumab q2w + Methotrexate | Percentage of Subjects Achieving ACR20 Response: Olokizumab Comparison With Adalimumab | 326 Participants |
| Arm 3: Adalimumab q2w + Methotrexate | Percentage of Subjects Achieving ACR20 Response: Olokizumab Comparison With Adalimumab | 309 Participants |
| Arm 4: Placebo q2w + Methotrexate | Percentage of Subjects Achieving ACR20 Response: Olokizumab Comparison With Adalimumab | 108 Participants |
Comparison: The ACR20 response rate for adalimumab was expected to be at least 52.5% at Week 12.p-value: <0.000195% CI: [0.148, 0.298]Chi-squared
Comparison: A noninferiority margin of 12% was used for the comparison between OKZ and adalimumab with respect to this endpoint.97.5% CI: [-0.022, 0.112]
Comparison: A noninferiority margin of 12% was used for the comparison between OKZ and adalimumab with respect to this endpoint.97.5% CI: [-0.035, 0.102]
Secondary
Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response
Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 24 American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
Time frame: at Week 24
Population: Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm 1: Olokizumab q4w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response | 240 Participants |
| Arm 2: Olokizumab q2w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response | 234 Participants |
| Arm 3: Adalimumab q2w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response | 214 Participants |
| Arm 4: Placebo q2w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response | 55 Participants |
p-value: <0.000197.5% CI: [0.192, 0.349]Chi-squared
p-value: <0.000197.5% CI: [0.195, 0.353]Chi-squared
95% CI: [0.165, 0.303]
Secondary
Percentage of Subjects Achieving Low Disease Activity
Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) \<3.2, and remaining on randomized treatment and in the study at Week 12
Time frame: at Week 12
Population: Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm 1: Olokizumab q4w + Methotrexate | Percentage of Subjects Achieving Low Disease Activity | 220 Participants |
| Arm 2: Olokizumab q2w + Methotrexate | Percentage of Subjects Achieving Low Disease Activity | 210 Participants |
| Arm 3: Adalimumab q2w + Methotrexate | Percentage of Subjects Achieving Low Disease Activity | 177 Participants |
| Arm 4: Placebo q2w + Methotrexate | Percentage of Subjects Achieving Low Disease Activity | 31 Participants |
Comparison: The DAS28 low disease activity (based on DAS28 \[CRP\] \<3.2) response rate at Week 12 is estimated to be 10% in the placebo group and 22% in the 64 mg q4w OKZ group, resulting in an expected difference of 12 percentage points between respective OKZ group and placebo.p-value: <0.000197.5% CI: [0.257, 0.397]Chi-squared
Comparison: The DAS28 low disease activity (based on DAS28 \[CRP\] \<3.2) response rate at Week 12 is estimated to be 10% in the placebo group and 30% in the 64 mg q2w OKZ group, resulting in an expected difference of 20 percentage points between respective OKZ group and placebo.p-value: <0.000197.5% CI: [0.25, 0.391]Chi-squared
Secondary
Percentage of Subjects Achieving Low Disease Activity: Olokizumab Comparison With Adalimumab
Percentage of subjects achieving low disease activity, defined as DAS28 (CRP) \<3.2, and remaining on randomized treatment and in the study at Week 12; served to demonstrate that the efficacy of OKZ was noninferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) was demonstrated concurrently based on the same endpoint
Time frame: at Week 12
Population: Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm 1: Olokizumab q4w + Methotrexate | Percentage of Subjects Achieving Low Disease Activity: Olokizumab Comparison With Adalimumab | 220 Participants |
| Arm 2: Olokizumab q2w + Methotrexate | Percentage of Subjects Achieving Low Disease Activity: Olokizumab Comparison With Adalimumab | 210 Participants |
| Arm 3: Adalimumab q2w + Methotrexate | Percentage of Subjects Achieving Low Disease Activity: Olokizumab Comparison With Adalimumab | 177 Participants |
| Arm 4: Placebo q2w + Methotrexate | Percentage of Subjects Achieving Low Disease Activity: Olokizumab Comparison With Adalimumab | 31 Participants |
Comparison: The DAS28 low disease activity response rate for adalimumab was expected to be at least 27% at Week 12.p-value: <0.000195% CI: [0.191, 0.313]Chi-squared
Comparison: A noninferiority margin of 7.5% was used for the comparison between OKZ and adalimumab with respect to this endpoint.97.5% CI: [0.004, 0.147]
Comparison: A noninferiority margin of 7.5% was used for the comparison between OKZ and adalimumab with respect to this endpoint.97.5% CI: [-0.003, 0.141]
Secondary
Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)
Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 24
Time frame: at Week 24
Population: Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm 1: Olokizumab q4w + Methotrexate | Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission) | 58 Participants |
| Arm 2: Olokizumab q2w + Methotrexate | Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission) | 51 Participants |
| Arm 3: Adalimumab q2w + Methotrexate | Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission) | 60 Participants |
| Arm 4: Placebo q2w + Methotrexate | Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission) | 10 Participants |
p-value: 0.000397.5% CI: [0.031, 0.123]Chi-squared
p-value: 0.00197.5% CI: [0.02, 0.111]Chi-squared
95% CI: [0.046, 0.127]